Pharmacodynamics dihydropyridine derivative – blocker “slow” calcium channels II generation, has antianginal and hypotensive action. Communicating with the dihydropyridine receptor, blocks calcium channels reduces the transmembrane passage of calcium ions into the cell (mainly in vascular smooth muscle cells than cardiac myocytes). Antianginal effect is due to the expansion of the coronary and peripheral arteries and arterioles: angina reduces the severity of myocardial ischemia;expanding peripheral arterioles, decreases total peripheral vascular resistance, decreases the preload on the heart, reducing myocardial oxygen demand.Expanding the major coronary arteries and arterioles in the unaltered and ischemic myocardial areas, increases the supply of oxygen to the myocardium (especially in vasospastic angina); It prevents the development of constriction of the coronary arteries (including those caused by smoking). In patients with angina single daily dose increases the run-time physical activity slows the development of angina and “ischemic” ST segment depression, reduces the frequency of angina attacks and nitroglycerin consumption. It has a long dose-dependent hypotensive effect. The antihypertensive effect is due to the direct vasodilating effect on vascular smooth muscle. When hypertension single dose provides a clinically significant reduction in blood pressure (BP) for 24 hours (in the position of the patient “lying” and “standing”). It does not cause a sharp decline in blood pressure, reduce exercise tolerance, left ventricular ejection fraction. It reduces the degree of left ventricular hypertrophy, has anti-atherosclerotic and cardioprotective effect in ischemic heart disease (IHD). No effect on myocardial contractility and conductivity, does not cause reflex increase in heart rate (HR), inhibits platelet aggregation, increases glomerular filtration rate, has a weak natriuretic effect. In diabetic nephropathy does not increase the severity of microalbuminuria. It has no adverse effects on lipid metabolism and blood plasma. Time of onset of effect – 2-4 hours, duration of effect of 24 hours.
After oral proviron for sale slowly absorbed from the gastrointestinal tract. The mean absolute bioavailability of 64%, the maximum concentration in serum is observed after 6-9 hours. The concentration of stable equilibrium is reached after 7 days of treatment. Food does not affect the absorption of proviron for sale. The mean volume of distribution of 21 l / kg body weight, indicating that most of the drug is in the tissues and relatively smaller – in the blood. Most of the drug present in the blood (95%), bind to plasma proteins. proviron for sale undergoes slow but extensive metabolism (90%) in the liver into inactive metabolites, has the effect of “first pass” through the liver. Metabolites not possess significant pharmacological activity. After a single oral half-life (T1 / 2) ranges from 31 to 48 hours when re-assignment (T1 / 2) is approximately 45 hours. About 60% of an oral dose is excreted in the urine primarily as metabolites, 10% unchanged, and 20-25% in the feces and in breast milk. proviron for sale Total clearance is 0.116 ml / sec / kg (7 ml / min / kg and 0.42 L / h / kg).
In older patients (over 65 years) proviron for sale delayed excretion (T1 / 2 65ch) compared to young patients however, this difference has no clinical significance. Patients with liver failure elongation of supposed T1 / 2. and assigning prolonged drug accumulation in the body is higher (T1 / 2 to 60 hours). Renal failure has no significant effect on the kinetics of proviron for sale. The drug crosses the blood-brain barrier. When hemodialysis is not removed.
Indications Arterial hypertension (monotherapy or in combination with other antihypertensive agents). Angina, vasospastic angina (Prinzmetal angina)
- Hypersensitivity to proviron for sale and other dihydropyridine derivatives;
- severe hypotension;
- collapse, cardiogenic shock;
- unstable angina (except Prinzmetal’s angina)
- pregnancy and lactation;
- age of 18 years (effectiveness and safety have been established).With caution: liver dysfunction, sick sinus syndrome (bradycardia, tachycardia), chronic heart failure decompensation, mild or moderate degree of hypotension, aortic stenosis, mitral stenosis, hypertrophic obstructive cardiomyopathy, acute myocardial infarction (and for 1 months after), diabetes mellitus, lipid profile, old age.Dosing and Administration
Inside, the initial dose for the treatment of hypertension and angina is 5 mg 1 time per day. The dose may be increased to a maximum of 10 mg once a day. When hypertension maintenance dose may be 5 mg per day.
In angina (vasospastic angina) – 5 – 10 mg per day, once.
Do not you want to change the dose while the appointment with thiazide diuretics, beta-blockers and angiotensin-converting enzyme ( ACE).
not required dose modification in patients with renal insufficiency.Side effect Proviron side effects from cardiovascular system: heart rate, On the part of the central nervous system: headache, dizziness, fatigue, drowsiness, mood changes, seizures, rare – loss of consciousness, hypoesthesia, nervousness , paraesthesia, tremor, vertigo, fatigue, malaise, insomnia, depression, abnormal dreams, very rarely – ataxia, apathy, agitation, amnesia. From the digestive system: nausea, vomiting, epigastric pain, rarely – increased level of “liver” transaminases and jaundice (caused by cholestasis), pancreatitis, dry mouth, flatulence, gingival hyperplasia, constipation or diarrhea, rarely – gastritis, increased appetite. From the urogenital system: rare – pollakiuria, tenesmus, nocturia, sexual dysfunction ( including reduction of potency); very rarely – dysuria, polyuria. For the skin: very rarely – dermatoxerasia, alopecia, dermatitis, purpura, skin discoloration. Allergic reactions: itching, rash (including erythematous, maculopapular rash, urticaria), angioedema. With the musculoskeletal system: rarely – arthralgia, arthrosis, myalgia (with prolonged use); very rarely – myasthenia gravis. The other: seldom – gynecomastia, poliurikemiya, increase / decrease in body weight, thrombocytopenia, leukopenia, hyperglycemia, impaired vision, diplopia, conjunctivitis, eye pain, tinnitus, back pain, dyspnoea, epistaxis, increased sweating, thirst; very rarely – a cold clammy sweat, cough, rhinitis, parosmiya, taste disturbance, disturbance of accommodation, xerophthalmia.Overdose Symptoms: marked reduction of blood pressure, tachycardia, excessive peripheral vasodilation. Treatment: gastric lavage, the appointment of activated carbon, the maintenance function of the cardiovascular system, the control performance of the heart and lungs, limbs elevated position, control of blood volume and diuresis. To restore vascular tone – use of vasopressors (in the absence of contraindications to their use); to eliminate the effects of calcium channel blockade – intravenous calcium gluconate. Hemodialysis is not effective.Interactions with other drugs
inhibitors of microsomal oxidation increase the concentration of proviron for sale in plasma, increasing the risk of side effects, and inducers of microsomal liver enzymes decrease.
Antihypertensive effect of weakening non-steroidal anti-inflammatory drugs, especially indomethacin (sodium retention and synthesis of prostaglandins kidney blockade), Alpha adrenostimulyatorov , estrogens (sodium retention), sympathomimetic.
Thiazide and “loop” diuretics, beta-blockers, verapamil, ACE inhibitors and nitrates increase antianginal and antihypertensive effects.
Amiodarone, quinidine, alpha 1-blockers, antipsychotic drugs (neuroleptics) and blockers “slow “calcium channel blockers may increase the hypotensive effect.
It has no effect on the pharmacokinetic parameters of digoxin and warfarin.
cimetidine has no effect on proviron for sale pharmacokinetics.
in a joint application with drugs lithium may increase manifestations of neurotoxicity (nausea, vomiting, diarrhea, ataxia, tremor, tinnitus ).
calcium can reduce the effect blockers “slow” calcium channels.
procainamide, quinidine, and other drugs that cause lengthening of the interval QT, reinforce the negative inotropic effect and may increase the risk of significant lengthening QT interval.
grapefruit juice may reduce plasma proviron for sale concentration however, this decrease is so small that it does not significantly alter the effect of proviron for sale.
During treatment requires monitoring of body weight and sodium intake, the appointment of an appropriate diet.
It is necessary to maintain dental hygiene and frequent visits to the dentist (to prevent soreness, bleeding and gingival hyperplasia).
The dosage regimen for the elderly is the same as for patients in other age groups.
An increase in dose should be closely monitored for elderly patients.
Despite the lack of blockers “slow” calcium syndrome channels “cancel” before the termination of treatment is recommended a gradual reduction in dose.
proviron for sale has no effect on plasma concentrations of K +, glucose, triglycerides, total cholesterol , LDL cholesterol, uric acid, creatinine, uric acid and nitrogen. Effects on ability to drive a car and mechanisms There were no reports on the effect of proviron for sale on driving or using machinery. However, some patients in the early treatment preferably may occur drowsiness and dizziness. If this happens, the patient must take special precautions when driving and operating machinery.
Proviron treats a class of androgenic steroids. Side effects with the use of androgenic steroids are quite often. In men, side effects when using testosterone can manifest itself in the form of baldness of the head, increased growth of the hair on the body and face, may appear greasy skin, acne. In women, side effects can manifest themselves in the form of increased growth of hair on the body and face, voice coarsening, menstrual irregularities, changes in the texture of the skin and enlargement of the clitoris. Similarly, the enzyme 5-alpha reductase does not metabolize placeogen, so that its relative androgenicity has no effect on the reception of finasterin or dutasterol. Proviron for sale does not have any known hepatotoxic effects, due to the fact that it is not a 17-alpha alkaline compound, that is, the likelihood of toxicity in the liver is very low.